Agneta Zickert Selected Research

Agneta Zickert Research Topics

Disease

20	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2022 - 01/2009
12	Lupus Nephritis 01/2021 - 01/2009
7	Nephritis 01/2020 - 01/2009
3	Autoimmune Diseases (Autoimmune Disease) 02/2019 - 02/2012
2	Thrombosis (Thrombus) 06/2022 - 07/2021
2	Chronic Disease (Chronic Diseases) 01/2019 - 01/2019
2	Inflammation (Inflammations) 01/2019 - 01/2018
2	Fatigue 01/2019 - 04/2017
2	Venous Thrombosis (Deep-Vein Thrombosis) 06/2013 - 03/2013
1	Genetic Predisposition to Disease (Genetic Predisposition) 06/2022
1	Venous Thromboembolism 07/2021
1	Albuminuria 01/2019
1	Arthritis (Polyarthritis) 01/2019
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2018
1	Pain (Aches) 04/2017
1	Leukopenia 01/2017
1	Systemic Scleroderma (Systemic Sclerosis) 01/2017
1	Lymphopenia (Lymphocytopenia) 01/2017
1	Rheumatoid Arthritis 08/2015
1	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 04/2015
1	Chronic Kidney Failure (Chronic Renal Failure) 04/2015
1	Glomerulonephritis 01/2015
1	Vascular Diseases (Vascular Disease) 06/2013
1	Heart Diseases (Heart Disease) 03/2013
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 03/2013
1	Atypical Hemolytic Uremic Syndrome 01/2011
1	Kidney Diseases (Kidney Disease) 01/2011

Drug/Important Bio-Agent (IBA)

7	AntibodiesIBA 06/2022 - 01/2009
7	AutoantibodiesIBA 01/2022 - 01/2009
5	Antiphospholipid AntibodiesIBA 06/2022 - 06/2013
5	belimumabIBA 05/2020 - 04/2017
4	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2015
3	HLA-DRB1 Chains (HLA DRB1)IBA 06/2022 - 04/2015
3	Rituximab (Mabthera)FDA Link 01/2021 - 05/2013
3	CreatinineIBA 01/2020 - 04/2015
3	Complement System Proteins (Complement)IBA 01/2019 - 01/2011
3	InterferonsIBA 01/2019 - 01/2016
2	Prothrombin (Factor II)IBA 06/2022 - 07/2021
2	CytokinesIBA 05/2020 - 01/2017
2	Antigen-Antibody Complex (Immune Complex)IBA 11/2019 - 10/2016
2	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2017 - 01/2017
2	Phospholipids (Phosphatides)FDA LinkGeneric 04/2015 - 03/2013
1	Cardiolipins (Cardiolipin)IBA 06/2022
1	PhosphatidylserinesIBA 06/2022
1	Immunoglobulin A (IgA)IBA 07/2021
1	Activated-Leukocyte Cell Adhesion Molecule (Neurolin)IBA 01/2020
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 01/2020
1	anti-dsDNA autoantibodyIBA 11/2019
1	DNA (Deoxyribonucleic Acid)IBA 11/2019
1	Histones (Histone)IBA 11/2019
1	Interferon Type IIBA 01/2019
1	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 01/2019
1	ametantrone (HAQ)IBA 01/2019
1	Stem Cell FactorIBA 01/2018
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2018
1	Epidermal Growth Factor (EGF)IBA 01/2018
1	Platelet-Derived Growth FactorIBA 01/2018
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2018
1	Serum AlbuminIBA 01/2018
1	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 01/2018
1	Matrix Metalloproteinases (MMPs)IBA 01/2018
1	AlbuminsIBA 01/2018
1	Prostaglandins AIBA 04/2017
1	Biological ProductsIBA 04/2017
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2017
1	Interferon LambdaIBA 01/2017
1	Gonadal Steroid Hormones (Sex Hormones)IBA 01/2017
1	Interleukin-17 (Interleukin 17)IBA 02/2015
1	Interleukin-23 (Interleukin 23)IBA 02/2015
1	B-Cell Activating FactorIBA 01/2015
1	LigandsIBA 01/2015
1	HLA-DRB1*04 antigenIBA 06/2013
1	Immunoglobulin G (IgG)IBA 03/2013
1	Immunoglobulin M (IgM)IBA 03/2013
1	HLA-DR3 Antigen (HLA DR3 Antigen)IBA 01/2013
1	HMGB1 Protein (HMG1)IBA 02/2012
1	Proteins (Proteins, Gene)FDA Link 02/2012
1	Complement Factor H (Factor H)IBA 01/2011
1	Complement Inactivating AgentsIBA 01/2011
1	C-Reactive ProteinIBA 01/2009

Therapy/Procedure

5	Therapeutics 01/2019 - 01/2009
1	Aftercare (After-Treatment) 02/2015